A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Public ClinicalTrials.gov record NCT06323161. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medicine (once-daily insulin with or without metformin). For each participant, the study will last for about one year.
Study identification
- NCT ID
- NCT06323161
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 274 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2024
- Primary completion
- Sep 8, 2025
- Completion
- Oct 22, 2025
- Last update posted
- Sep 8, 2026
2024 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valley Research | Fresno | California | 93720 | — |
| Valley Clinical Trials, Inc. | Northridge | California | 91325 | — |
| Bioclinical Research Alliance | Miami | Florida | 33155 | — |
| Solaris Clinical Research | Meridian | Idaho | 83646 | — |
| Iowa Diab & Endo Res Center | West Des Moines | Iowa | 50266 | — |
| Alliance for Multispec Res | Newton | Kansas | 67114 | — |
| Endo and Metab Consultants | Rockville | Maryland | 20852 | — |
| Elite Research Center | Flint | Michigan | 48532 | — |
| Palm Research Center Inc. | Las Vegas | Nevada | 89128 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27614 | — |
| Holston Medical Group | Kingsport | Tennessee | 37660 | — |
| Clinical Research Associates | Nashville | Tennessee | 37203 | — |
| Velocity Clinical Res-Dallas | Dallas | Texas | 75230 | — |
| Synergy Groups Medical | Houston | Texas | 77061 | — |
| PlanIt Research, PLLC | Houston | Texas | 77079 | — |
| Simcare Medical Research, LLC | Sugar Land | Texas | 77478 | — |
| Manassas Clinical Research Center | Manassas | Virginia | 20110 | — |
| TPMG Clinical Research | Newport News | Virginia | 23606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06323161, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06323161 live on ClinicalTrials.gov.